keyword
MENU ▼
Read by QxMD icon Read
search

Aml relapse treatment

keyword
https://www.readbyqxmd.com/read/28916904/early-assessment-of-response-to-induction-therapy-in-acute-myeloid-leukemia-using-18-f-flt-pet-ct
#1
Eun Ji Han, Bo-Hee Lee, Jeong-A Kim, Young Ha Park, Woo Hee Choi
BACKGROUND: We evaluated the suitability of (18)F-fluorodeoxythymidine ((18)F-FLT) positron emission tomography (PET)/computed tomography (CT) for assessment of the early response to induction therapy and its value for predicting clinical outcome in patients with acute myeloid leukemia (AML). Adult patients who had histologically confirmed AML and received induction therapy were enrolled. All patients underwent (18)F-FLT PET/CT after completion of induction. PET/CT images were visually and quantitatively assessed...
September 16, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28910431/hla-mismatched-microtransplant-in-older-patients-newly-diagnosed-with-acute-myeloid-leukemia-results-from-the-microtransplantation-interest-group
#2
Mei Guo, Nelson J Chao, Jian-Yong Li, David A Rizzieri, Qi-Yun Sun, Ann Mohrbacher, Elizabeth F Krakow, Wan-Jun Sun, Xu-Liang Shen, Xin-Rong Zhan, De-Pei Wu, Li Liu, Juan Wang, Min Zhou, Lin-Hua Yang, Yang-Yi Bao, Zheng Dong, Bo Cai, Kai-Xun Hu, Chang-Lin Yu, Jian-Hui Qiao, Hong-Li Zuo, Ya-Jing Huang, Anthony D Sung, Jun-Xiao Qiao, Zhi-Qing Liu, Tie-Qiang Liu, Bo Yao, Hong-Xia Zhao, Si-Xuan Qian, Wei-Wei Liu, Rafael Forés, Rafael F Duarte, Hui-Sheng Ai
Importance: The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients. Objective: To evaluate outcomes in different age groups among older patients with newly diagnosed AML who receive HLA-mismatched microtransplant. Design, Setting, and Participants: This multicenter clinical study included 185 patients with de novo AML at 12 centers in China, the United States, and Spain in the Microtransplantation Interest Group...
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28900115/a-phase-ii-study-of-arginine-deiminase-adi-peg20-in-relapsed-refractory-or-poor-risk-acute-myeloid-leukemia-patients
#3
Hui-Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung, Gautam Borthakur, Sheng-Fung Lin, Naveen Pemmaraju, Elias Jabbour, John S Bomalaski, Ya-Ping Chen, Hui-Hua Hsiao, Ming-Chung Wang, Ching-Yuan Kuo, Hung Chang, Su-Peng Yeh, Jorge Cortes, Li-Tzong Chen, Tsai-Yun Chen
Exogenous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers. Arginine deiminase (ADI) inhibits growth in various ASS-deficient cancers by depleting arginine. The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (AML) was evaluated in 43 patients in a prospective, phase II trial (NCT01910012 (10/07/2013), https://clinicaltrials.gov/ct2/show/NCT01910012?term = ADI-PEG20&rank = 12 ). Despite almost all pre-treatment tumor samples showing ASS deficiency, the best response among 21 evaluable patients was complete response (CR) in 2 (9...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28883285/genetic-abnormalities-in-core-binding-factor-acute-myeloid-leukemia
#4
Yuichi Ishikawa
Acute myeloid leukemia (AML) is a genetically heterogeneous disease, and its prognosis is stratified on the basis of chromosomal and genetic alterations. Core binding factor (CBF) leukemia consists of AML with t (8;21) (p22;q22) and inv16 (q16q16) /t (16;16) (q16;q16) and is included in AML with recurrent genetic abnormality according to WHO classification. Although CBF-AML is categorized as favorable-risk AML, approximately 40% of patients show relapse. The t (8;21) and inv16 (q16q16) /t (16;16) (q16;q16) result in RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes, respectively; however, the fusion proteins encoded by these genes alone are insufficient for the development of leukemia...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28883267/acute-myeloid-leukemia-in-adolescents-and-young-adults-from-the-viewpoint-of-pediatricians
#5
Daisuke Tomizawa, Souichi Adachi
It is well known that adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) should be treated based on pediatric ALL protocol, which could yield better survival rates. However, an optimal treatment strategy for AYAs with acute myeloid leukemia (AML) is not yet established and corresponding data are limited. Compared with ALL, clinical and biological characteristics of pediatric and adult AML are relatively similar. Moreover, treatment strategy is quite similar, although pediatric protocols are more intensive and transplant indications are narrower...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28879540/enasidenib-first-global-approval
#6
Esther S Kim
Enasidenib (Idhifa(®)) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation as detected by an FDA-approved test. It is at various stages of development in other countries for AML, myelodysplastic syndromes and solid tumours. This article summarizes the milestones in the development of enasidenib leading to this first global approval in the USA for the treatment of adults with relapsed or refractory IDH2-mutated AML...
September 6, 2017: Drugs
https://www.readbyqxmd.com/read/28868277/extramedullary-relapse-of-acute-myelogenous-leukemia-presenting-as-a-large-serous-retinal-detachment
#7
Wesley Green, P Kumar Rao, George J Harocopos
BACKGROUND/AIMS: To describe the rare presentation of a large, unilateral, serous retinal detachment as an extramedullary manifestation of acute myelogenous leukemia (AML) recurrence without bone marrow or central nervous system involvement after more than 1 year of follow-up. METHODS: Case report. RESULTS: A teenage patient with AML, previously treated with multiple courses of systemic chemotherapy, radiation, and bone marrow transplant, presented with acute vision loss...
July 2017: Ocular Oncology and Pathology
https://www.readbyqxmd.com/read/28864289/phase-1-clinical-trial-of-adoptive-immunotherapy-using-off-the-shelf-activated-natural-killer-cells-in-patients-with-refractory-and-relapsed-acute-myeloid-leukemia
#8
Michael Boyiadzis, Mounzer Agha, Robert L Redner, Alison Sehgal, Annie Im, Jing-Zhou Hou, Rafic Farah, Kathleen A Dorritie, Anastasios Raptis, Seah H Lim, Hong Wang, Natalia Lapteva, Zhuyong Mei, Lisa H Butterfield, Cliona M Rooney, Theresa L Whiteside
BACKGROUND AIMS: Activated NK cells (aNK) generated by expansion of a human interleukin-2-dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity. This phase 1 study evaluated feasibility, safety, and activity of aNK cells adoptively transferred to patients with refractory/relapsed acute myeloid leukemia (AML). In addition, effects of these aNK cells on the patient's immune system were evaluated. METHODS: Two cell-dose levels (1 × 10(9) cells/m(2) and 3 × 10(9) cells/m(2)) were used...
August 29, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28864170/flag-ida-regimen-as-bridge-therapy-to-allotransplantation-in-refractory-relapsed-acute-myeloid-leukemia-patients
#9
Mario Delia, Domenico Pastore, Paola Carluccio, Crescenza Pasciolla, Alessandra Ricco, Antonella Russo Rossi, Paola Casieri, Anna Mestice, Francesco Albano, Giorgina Specchia
BACKGROUND: Patients with primary refractory or first relapse acute myeloid leukemia (AML) are considered to have worse clinical outcomes after treatment. For these patients, the achievement of complete remission appears crucial for them to be able to undergo allotransplantation, which might be the only possible treatment. PATIENTS AND METHODS: We used the FLAG-Ida (fludarabine, cytarabine [cytosine arabinoside], granulocyte colony-stimulating factor, idarubicin) regimen in patients with primary refractory/first relapse AML as a bridge to transplantation...
June 19, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28860803/therapies-for-acute-myeloid-leukemia-vosaroxin
#10
REVIEW
Hamid Sayar, Parvaneh Bashardoust
Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising drug for the treatment of acute myeloid leukemia (AML). Early-stage clinical trials with this agent led to a large randomized double-blind placebo-controlled study of vosaroxin in combination with intermediate-dose cytarabine for the treatment of relapsed or refractory AML. The study demonstrated better complete remission rates with vosaroxin, but there was no statistically significant overall survival benefit in the whole cohort...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28857842/relapsed-refractory-acute-myeloid-leukemia-any-progress
#11
Richard F Schlenk, Carsten Müller-Tidow, Axel Benner, Meinhard Kieser
PURPOSE OF REVIEW: Aim of this review was to focus on prognostic and predictive factors, standard and new treatment approaches, and on statistical considerations for future clinical trials in patients with relapsed/refractory acute myeloid leukemia (r/r-AML). RECENT FINDINGS: New prognostic molecular markers were identified in r/r-AML, FLT3-ITD, mutated IDH1, and biallelic CEBPA mutations. Intensive combination chemotherapy including gemtuzumab ozogamicin emerged as an effective salvage therapy in refractory AML...
August 28, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28851445/chimeric-antigen-receptors-for-adoptive-t-cell-therapy-in-acute-myeloid-leukemia
#12
REVIEW
Mingxue Fan, Minghao Li, Lipeng Gao, Sicong Geng, Jing Wang, Yiting Wang, Zhiqiang Yan, Lei Yu
Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology...
August 29, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28832804/complex-karyotype-including-ring-chromosome-11-in-a-patient-with-acute-myeloid-leukemia-case-report
#13
Maria Helena Faria Ornellas, Maria Christina Paixão Maioli, Stella Beatriz Sampaio Gonçalves de Lucena, Elenice Ferreira Bastos, Tatiana Silva Chaves, Karina Vieira de Melo, Marilza de Moura Ribeiro-Carvalho, Thomas Liehr, Gilda Alves
CONTEXT: Complex karyotypes in acute myeloid leukemia (AML) are characterized by an overall low response rate with frequent relapses after clinical treatment. CASE REPORT: Here, we describe the case of a 61-year-old obese female with clinically diagnosed AML who presented a complex karyotype involving an uncommon abnormality: ring chromosome 11. Immunophenotypic analysis confirmed the diagnosis. Classical and molecular cytogenetic analyses, using GTG banding and FISH (fluorescence in situ hybridization), revealed the presence of complex structural rearrangement involving r(11), add(12)(p13), der(5) and der(13)...
August 21, 2017: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/28830889/dendritic-cell-vaccination-as-post-remission-treatment-to-prevent-or-delay-relapse-in-acute-myeloid-leukemia
#14
Sébastien Anguille, Ann L Van de Velde, Evelien L Smits, Viggo F Van Tendeloo, Gunnar Juliusson, Nathalie Cools, Griet Nijs, Barbara Stein, Eva Lion, Ann Van Driessche, Irma Vandenbosch, Anke Verlinden, Alain P Gadisseur, Wilfried A Schroyens, Ludo Muylle, Katrien Vermeulen, Marie-Berthe Maes, Kathleen Deiteren, Ronald Malfait, Emma Gostick, Martin Lammens, Marie M Couttenye, Philippe Jorens, Herman Goossens, David A Price, Kristin Ladell, Yoshihiro Oka, Fumihiro Fujiki, Yusuke Oji, Haruo Sugiyama, Zwi N Berneman
Relapse is a major problem in acute myeloid leukemia (AML) and adversely impacts survival. In this phase II study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) mRNA as post-remission treatment in 30 AML patients at very high risk of relapse. There was a demonstrable anti-leukemic response in 13 patients. Nine patients achieved molecular remission as demonstrated by normalization of WT1 transcript levels, 5 of which are sustained after a median follow-up of 109...
August 22, 2017: Blood
https://www.readbyqxmd.com/read/28828165/angiogenesis-status-in-patients-with-acute-myeloid-leukemia-from-diagnosis-to-post-hematopoietic-stem-cell-transplantation
#15
REVIEW
M Mohammadi Najafabadi, K Shamsasenjan, P Akbarzadehalaleh
As already proven in solid tumors, increased angiogenesis leads to increased number of blood vessels, resulting in unfavorable outcomes and resistance to chemotherapy. It was previously thought that angiogenesis plays no role in the pathogenesis of acute myeloid leukemia (AML), due to the fact that AML is a liquid tumor. However, many studies have suggested that increased angiogenesis has important roles in patients with AML, including increased numbers of vessels in bone marrow and pro-angiogenic factors, as well as decreased anti-angiogenic factors...
2017: International Journal of Organ Transplantation Medicine
https://www.readbyqxmd.com/read/28825596/ultrasensitive-mutation-detection-identifies-rare-residual-cells-causing-acute-myelogenous-leukemia-relapse
#16
Brian Parkin, Angelina Londoño-Joshi, Qing Kang, Muneesh Tewari, Andrew D Rhim, Sami N Malek
Acute myelogenous leukemia (AML) frequently relapses after complete remission (CR), necessitating improved detection and phenotypic characterization of treatment-resistant residual disease. In this work, we have optimized droplet digital PCR to broadly measure mutated alleles of recurrently mutated genes in CR marrows of AML patients at levels as low as 0.002% variant allele frequency. Most gene mutations persisted in CR, albeit at highly variable and gene-dependent levels. The majority of AML cases demonstrated residual aberrant oligoclonal hematopoiesis...
August 21, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28822593/decreased-expression-of-microrna-122-is-associated-with-an-unfavorable-prognosis-in-childhood-acute-myeloid-leukemia-and-function-analysis-indicates-a-therapeutic-potential
#17
Juan Yang, Yufang Yuan, Xiaochun Yang, Ze Hong, Lijuan Yang
MicroRNA (miR)-122 functions as a tumor suppressor in various human cancers. However, its involvement in childhood acute myeloid leukemia (AML) remains unknown. In this study, quantitative real-time PCR assay demonstrated that miR-122 expression in bone marrow specimens from AML children were significantly lower than that in non-malignant controls (P<0.001). Statistically, AML children with low miR-122 expression more frequently had large white blood cell count (P=0.022), French-American-British classification subtype M7 (P<0...
June 28, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28814980/cooperative-effect-of-chidamide-and-chemotherapeutic-drugs-induce-apoptosis-by-dna-damage-accumulation-and-repair-defects-in-acute-myeloid-leukemia-stem-and-progenitor-cells
#18
Yin Li, Yan Wang, Yong Zhou, Jie Li, Kai Chen, Leisi Zhang, Manman Deng, Suqi Deng, Peng Li, Bing Xu
BACKGROUND: Many conventional chemotherapeutic drugs are known to be involved in DNA damage, thus ultimately leading to apoptosis of leukemic cells. However, they fail to completely eliminate leukemia stem cells (LSCs) due to their higher DNA repair capacity of cancer stem cells than that of bulk cancer cells, which becomes the root of drug resistance and leukemia recurrence. A new strategy to eliminate LSCs in acute myeloid leukemia (AML) is therefore urgently needed. RESULTS: We report that a low-dose chidamide, a novel orally active benzamide-type histone deacetylase (HDAC) inhibitor, which selectively targets HDACs 1, 2, 3, and 10, could enhance the cytotoxicity of DNA-damaging agents (daunorubicin, idarubicin, and cytarabine) in CD34(+)CD38(-) KG1α cells, CD34(+)CD38(-) Kasumi cells, and primary refractory or relapsed AML CD34(+) cells, reflected by the inhibition of cell proliferation, induction of apoptosis, and increase of cell cycle arrest in vitro...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28812191/improved-outcome-of-childhood-acute-myeloid-leukemia-in-an-eastern-european-country-lithuanian-experience
#19
Igne Kairiene, Ramune Pasauliene, Nadezda Lipunova, Goda Vaitkeviciene, Lina Rageliene, Jelena Rascon
The reported treatment outcomes of children treated for cancer in Eastern European countries are inferior to those in Northern/Western Europe. We hypothesized that recent survival rates could be comparable to the current standards and performed a population-based analysis of treatment outcome of childhood acute myeloid leukemia (AML) in Lithuania, a small Eastern European country. Children < 18 years old who were treated for AML from 2000 to 2013 were included (n = 54). Estimates of 5-year event-free (EFS5y) and overall survival (OS5y) rates were analyzed...
August 15, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28804680/treatment-of-older-patients-with-acute-myeloid-leukemia-aml-revised-canadian-consensus-guidelines
#20
REVIEW
Joseph M Brandwein, Nancy Zhu, Rajat Kumar, Brian Leber, Mitchell Sabloff, Irwindeep Sandhu, Jeannine Kassis, Harold J Olney, Mohamed Elemary, Andre C Schuh
The treatment of acute myeloid leukemia (AML) in older patients is undergoing rapid changes, with a number of important publications in the past five years. Because of this, a group of Canadian leukemia experts has produced an update to the Canadian Consensus Guidelines that were published in 2013, with several new agents recommended, subject to availability. Recent studies have supported the survival benefit of induction chemotherapy for patients under age 80, except those with major co-morbidities or those with adverse risk cytogenetics who are not candidates for allogeneic hematopoietic stem cell transplantation (HSCT)...
2017: American Journal of Blood Research
keyword
keyword
121122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"